Torrent Pharmaceuticals has received a warning letter from the US Food and Drug Administration (USFDA) for its Indrad facility in Gujarat. This action by the USFDA follows earlier intimation received from the regulator in August 2019, wherein the agency had classified its inspection as ‘Official Action Indicated’ (OAI). The company is committed in maintaining the highest standards of compliances and quality manufacturing across all its facilities.
Torrent Pharmaceuticals is Flagship Company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.
